ML 221Apelin receptor (APJ) antagonist CAS# 877636-42-5 |
2D Structure
- BMN-673 8R,9S
Catalog No.:BCC1422
CAS No.:1207456-00-5
- XAV-939
Catalog No.:BCC1120
CAS No.:284028-89-3
- PJ34
Catalog No.:BCC1865
CAS No.:344458-19-1
- ABT-888 (Veliparib)
Catalog No.:BCC1267
CAS No.:912444-00-9
- Veliparib dihydrochloride
Catalog No.:BCC2076
CAS No.:912445-05-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 877636-42-5 | SDF | Download SDF |
PubChem ID | 7217941 | Appearance | Powder |
Formula | C17H11N3O6S | M.Wt | 385.35 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 31 mg/mL (80.45 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | [4-oxo-6-(pyrimidin-2-ylsulfanylmethyl)pyran-3-yl] 4-nitrobenzoate | ||
SMILES | C1=CN=C(N=C1)SCC2=CC(=O)C(=CO2)OC(=O)C3=CC=C(C=C3)[N+](=O)[O-] | ||
Standard InChIKey | UASIRTUMPRQVFY-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H11N3O6S/c21-14-8-13(10-27-17-18-6-1-7-19-17)25-9-15(14)26-16(22)11-2-4-12(5-3-11)20(23)24/h1-9H,10H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Apelin receptor (APJ) antagonist (IC50 values are 0.70 and 1.75 μM in a cAMP assay and β-arrestin assay, respectively). Displays >37-fold selectivity over the closely related angiotensin II type 1 (AT1) receptor. Exhibits no toxicity towards human hepatocytes at concentrations >50 μM. |
ML 221 Dilution Calculator
ML 221 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.595 mL | 12.9752 mL | 25.9504 mL | 51.9009 mL | 64.8761 mL |
5 mM | 0.519 mL | 2.595 mL | 5.1901 mL | 10.3802 mL | 12.9752 mL |
10 mM | 0.2595 mL | 1.2975 mL | 2.595 mL | 5.1901 mL | 6.4876 mL |
50 mM | 0.0519 mL | 0.2595 mL | 0.519 mL | 1.038 mL | 1.2975 mL |
100 mM | 0.026 mL | 0.1298 mL | 0.2595 mL | 0.519 mL | 0.6488 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Tandospirone
Catalog No.:BCC4208
CAS No.:87760-53-0
- Bryostatin 2
Catalog No.:BCC5619
CAS No.:87745-28-6
- H-Tyrosinol
Catalog No.:BCC2697
CAS No.:87745-27-5
- (R)-Crizotinib
Catalog No.:BCC1284
CAS No.:877399-52-5
- GPBAR-A
Catalog No.:BCC6201
CAS No.:877052-79-4
- Alismoxide
Catalog No.:BCN1265
CAS No.:87701-68-6
- 3-(1-Piperazinyl)-1,2-benzisothiazole
Catalog No.:BCC8585
CAS No.:87691-87-0
- Isomagnolol
Catalog No.:BCN8325
CAS No.:87688-90-2
- Pentoxyresorufin
Catalog No.:BCC6297
CAS No.:87687-03-4
- 6-Hydroxyrubiadin
Catalog No.:BCN4425
CAS No.:87686-86-0
- Trandolapril
Catalog No.:BCC5275
CAS No.:87679-37-6
- RO-9187
Catalog No.:BCC1904
CAS No.:876708-03-1
- Eupalinolide B
Catalog No.:BCN2525
CAS No.:877822-40-7
- Eupalinolide A
Catalog No.:BCN2524
CAS No.:877822-41-8
- erythro-Guaiacylglycerol beta-sinapyl ether
Catalog No.:BCN6605
CAS No.:877875-96-2
- TW-37
Catalog No.:BCC2257
CAS No.:877877-35-5
- 6beta-Hydroxyipolamiide
Catalog No.:BCN4426
CAS No.:87797-84-0
- Glucagon-like peptide 1 (1-37) (human, rat)
Catalog No.:BCC5827
CAS No.:87805-34-3
- S1RA
Catalog No.:BCC4189
CAS No.:878141-96-9
- Alismol
Catalog No.:BCN4427
CAS No.:87827-55-2
- Walrycin B
Catalog No.:BCC5156
CAS No.:878419-78-4
- Isosalviamine A
Catalog No.:BCN3553
CAS No.:878475-29-7
- Isosalviamine B
Catalog No.:BCN3554
CAS No.:878475-30-0
- JNJ 303
Catalog No.:BCC7806
CAS No.:878489-28-2
Resveratrol attenuates ICAM-1 expression and monocyte adhesiveness to TNF-alpha-treated endothelial cells: evidence for an anti-inflammatory cascade mediated by the miR-221/222/AMPK/p38/NF-kappaB pathway.[Pubmed:28338009]
Sci Rep. 2017 Mar 24;7:44689.
Resveratrol, an edible polyphenolic phytoalexin, improves endothelial dysfunction and attenuates inflammation. However, the mechanisms have not been thoroughly elucidated. Therefore, we investigated the molecular basis of the effects of resveratrol on TNF-alpha-induced ICAM-1 expression in HUVECs. The resveratrol treatment significantly attenuated the TNF-alpha-induced ICAM-1 expression. The inhibition of p38 phosphorylation mediated the reduction in ICAM-1 expression caused by resveratrol. Resveratrol also decreased TNF-alpha-induced IkappaB phosphorylation and the phosphorylation, acetylation, and translocation of NF-kappaB p65. Moreover, resveratrol induced the AMPK phosphorylation and the SIRT1 expression in TNF-alpha-treated HUVECs. Furthermore, TNF-alpha significantly suppressed miR-221/-222 expression, which was reversed by resveratrol. miR-221/-222 overexpression decreased p38/NF-kappaB and ICAM-1 expression, which resulted in reduced monocyte adhesion to TNF-alpha-treated ECs. In a mouse model of acute TNF-alpha-induced inflammation, resveratrol effectively attenuated ICAM-1 expression in the aortic ECs of TNF-alpha-treated wild-type mice. These beneficial effects of resveratrol were lost in miR-221/222 knockout mice. Our data showed that resveratrol counteracted the TNF-alpha-mediated reduction in miR-221/222 expression and decreased the TNF-alpha-induced activation of p38 MAPK and NF-kappaB, thereby suppressing ICAM-1 expression and monocyte adhesion. Collectively, our results show that resveratrol attenuates endothelial inflammation by reducing ICAM-1 expression and that the protective effect was mediated partly through the miR-221/222/AMPK/p38/NF-kappaB pathway.
Overexpression of miRNA-221 promotes cell proliferation by targeting the apoptotic protease activating factor-1 and indicates a poor prognosis in ovarian cancer.[Pubmed:28350128]
Int J Oncol. 2017 Mar 7.
MicroRNAs are a class of small non-coding, endogenous RNAs involved in cancer development and progression. MicroRNA-221 (mir-221) has been reported to have both an oncogenic and tumor-suppressive role in human tumors, but the role of miR-221 in ovarian cancer is poorly understood. In the present study, the expression levels of miR-221 and the apoptosis protease activating factor 1 (APAF1) protein in 63 samples of ovarian cancer tissues and the cell lines, IOSE25, A2780, OVCAR3, SKOV3 and 3AO were detected by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and western blot analysis, respectively. Cell proliferation was measured using cell counting kit-8 (CCK-8); cell migration and invasion were detected using a transwell assay; cell apoptosis was evaluated by flow cytometry and hoechst staining, and a luciferase assay was performed to verify a putative target site of miR-221 in the 3'-UTR of APAF1 mRNA. Expression of miR-221 was upregulated in ovarian cancer tissues. Patients with increased miR-221 expression levels had a reduced disease-free survival (P=0.0014) and overall survival (P=0.0058) compared with those with low miR-221 expression. Transfection of SKOV3 and A2780 cell lines with miR-221 inhibitor induced APAF1 protein expression, suppressed cell proliferation and migration and promoted tumor cell apoptosis. In conclusion, the APAF1 gene was confirmed as a direct target of miR-221 and overexpression of APAF1 suppressed ovarian cancer cell proliferation and induced cell apoptosis in vitro. These findings indicate that miR-221-APAF1 should be studied further as a potential new diagnostic or prognostic biomarker for ovarian cancer.
miRNA-101-1 and miRNA-221 expressions and their polymorphisms as biomarkers for early diagnosis of hepatocellular carcinoma.[Pubmed:28366737]
Infect Genet Evol. 2017 Jul;51:173-181.
BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth most common malignant tumor with an increasing incidence. Hepatitis C virus (HCV) is one of the major risk factors that lead to HCC development. MicroRNAs are conserved non-coding RNAs which regulate gene expression at the posttranscriptional level. They have been recently identified as important regulators that affect carcinogenesis. Of these miRNAs, are miR-221 and miR-101-1, which their aberrant expressions have been reported to play an important role in HCC. PATIENTS AND METHODS: In this study, we investigated the association between miR-221 and miR-101-1 polymorphisms and their expressions and the early prediction of HCC in HCV infected patients. Quantitative real-time PCR (qPCR) was done to estimate the expression levels of miRNA-221 and miRNA-101-1 in serum. To detect the genotyping of miR-221 and miR-101-1 related SNPs, DNA was extracted. Then, genotyping was performed using real-time PCR. RESULTS: We found that rs7536540 polymorphism in miR-101-1 is significantly associated with development of HCC. In addition, our results showed no significant association between rs17084733 polymorphism in miR-221 and HCC occurrence. We confirmed the upregulation of miR-221 and the downregulation of miR-101-1 in HCC. As regards HCV patients, miR-221and miR-101-1 were found to be upregulated. CONCLUSION: Both miR-221 and miR-101-1 expression levels may be useful as noninvasive diagnostic biomarkers for early prediction of HCC among HCV patients.
Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor.[Pubmed:23010269]
Bioorg Med Chem Lett. 2012 Nov 1;22(21):6656-60.
The recently discovered apelin/APJ system has emerged as a critical mediator of cardiovascular homeostasis and is associated with the pathogenesis of cardiovascular disease. A role for apelin/APJ in energy metabolism and gastrointestinal function has also recently emerged. We disclose the discovery and characterization of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221), a potent APJ functional antagonist in cell-based assays that is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor. ML221 was derived from an HTS of the ~330,600 compound MLSMR collection. This antagonist showed no significant binding activity against 29 other GPCRs, except to the kappa-opioid and benzodiazepinone receptors (<50/<70%I at 10 muM). The synthetic methodology, development of structure-activity relationship (SAR), and initial in vitro pharmacologic characterization are also presented.